Editas Medicine (EDIT) Current Leases (2019 - 2025)
Editas Medicine (EDIT) reported Current Leases of $6.0 million for Q4 2025, down 58.84% year-over-year from $14.7 million in Q4 2024, and down 0.94% on a QoQ basis from $6.1 million in Q3 2025.
Editas Medicine (EDIT) has 7 years of Current Leases data on file, last reported at $6.0 million in Q4 2025.
- Quarterly Current Leases fell 58.84% year-over-year to $6.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.0 million (down 58.84% YoY) and the FY2025 annual result came in at $6.0 million, down 58.84% from the prior year.
- Current Leases eased to $6.0 million in Q4 2025 per EDIT's latest filing, from $6.1 million in the prior quarter.
- Across five years, Current Leases topped out at $18.2 million in Q2 2024 and bottomed at $6.0 million in Q4 2025.
- The 5-year median for Current Leases is $10.3 million (2021), against an average of $10.7 million.
- The widest annual swing landed in 2024, when Current Leases jumped 76.03%; it then tumbled 66.2% in 2025.
- Tracing EDIT's Current Leases over 5 years: stood at $10.3 million in 2021, then advanced by 7.5% to $11.1 million in 2022, then climbed by 9.76% to $12.2 million in 2023, then advanced by 20.45% to $14.7 million in 2024, then tumbled by 58.84% to $6.0 million in 2025.
- Per Business Quant, the three latest EDIT Current Leases figures stand at $6.0 million (Q4 2025), $6.1 million (Q3 2025), and $6.1 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 83,991.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 7.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 720.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 45.66 Mn |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | 6.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.03 Mn |
| Sep 30, 2025 | 6.09 Mn |
| Jun 30, 2025 | 6.15 Mn |
| Mar 31, 2025 | 13.16 Mn |
| Dec 31, 2024 | 14.65 Mn |
| Sep 30, 2024 | 16.39 Mn |
| Jun 30, 2024 | 18.18 Mn |
| Mar 31, 2024 | 12.36 Mn |
| Dec 31, 2023 | 12.16 Mn |
| Sep 30, 2023 | 9.69 Mn |
| Jun 30, 2023 | 10.33 Mn |
| Mar 31, 2023 | 8.33 Mn |
| Dec 31, 2022 | 11.08 Mn |
| Sep 30, 2022 | 11.97 Mn |
| Jun 30, 2022 | 10.15 Mn |
| Mar 31, 2022 | 10.21 Mn |
| Dec 31, 2021 | 10.31 Mn |
| Sep 30, 2021 | 10.26 Mn |
| Jun 30, 2021 | 8.97 Mn |
| Mar 31, 2021 | 7.26 Mn |
| Dec 31, 2020 | 6.81 Mn |
| Sep 30, 2020 | 6.34 Mn |
| Jun 30, 2020 | 6.65 Mn |
| Mar 31, 2020 | 5.65 Mn |
| Dec 31, 2019 | 5.80 Mn |
| Sep 30, 2019 | 4.45 Mn |
| Jun 30, 2019 | 3.65 Mn |
| Mar 31, 2019 | 3.52 Mn |